Cargando…
Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes
BACKGROUND: Older nursing home (NH) residents with glycemic overtreatment are at significant risk of hypoglycemia and other harms and may benefit from deintensification. However, little is known about deintensification practices in this setting. METHODS: We conducted a cohort study from January 1, 2...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283249/ https://www.ncbi.nlm.nih.gov/pubmed/35318647 http://dx.doi.org/10.1111/jgs.17735 |
_version_ | 1784747283982581760 |
---|---|
author | Lederle, Lauren I. Steinman, Michael A. Jing, Bocheng Nguyen, Brian Lee, Sei J. |
author_facet | Lederle, Lauren I. Steinman, Michael A. Jing, Bocheng Nguyen, Brian Lee, Sei J. |
author_sort | Lederle, Lauren I. |
collection | PubMed |
description | BACKGROUND: Older nursing home (NH) residents with glycemic overtreatment are at significant risk of hypoglycemia and other harms and may benefit from deintensification. However, little is known about deintensification practices in this setting. METHODS: We conducted a cohort study from January 1, 2013 to December 31, 2019 among Veterans Affairs (VA) NH residents. Participants were VA NH residents age ≥65 with type 2 diabetes with a NH length of stay (LOS) ≥ 30 days and an HbA1c result during their NH stay. We defined overtreatment as HbA1c <6.5 with any insulin use, and potential overtreatment as HbA1c <7.5 with any insulin use or HbA1c <6.5 on any glucose‐lowering medication (GLM) other than metformin alone. Our primary outcome was continued glycemic overtreatment without deintensification 14 days after HbA1c. RESULTS: Of the 7422 included residents, 17% of residents met criteria for overtreatment and an additional 23% met criteria for potential overtreatment. Among residents overtreated and potentially overtreated at baseline, 27% and 19%, respectively had medication regimens deintensified (73% and 81%, respectively, continued to be overtreated). Long‐acting insulin use and hyperglycemia ≥300 mg/dL before index HbA1c were associated with increased odds of continued overtreatment (odds ratio [OR] 1.37, 95% confidence interval [CI] 1.14–1.65 and OR 1.35, 95% CI 1.10–1.66, respectively). Severe functional impairment (MDS‐ADL score ≥ 19) was associated with decreased odds of continued overtreatment (OR 0.72, 95% CI 0.56–0.95). Hypoglycemia was not associated with decreased odds of overtreatment. CONCLUSIONS: Overtreatment of diabetes in NH residents is common and a minority of residents have their medication regimens appropriately deintensified. Deprescribing initiatives targeting residents at high risk of harms and with low likelihood of benefit such as those with history of hypoglycemia, or high levels of cognitive or functional impairment are most likely to identify NH residents most likely to benefit from deintensification. |
format | Online Article Text |
id | pubmed-9283249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92832492022-10-14 Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes Lederle, Lauren I. Steinman, Michael A. Jing, Bocheng Nguyen, Brian Lee, Sei J. J Am Geriatr Soc Regular Issue Content BACKGROUND: Older nursing home (NH) residents with glycemic overtreatment are at significant risk of hypoglycemia and other harms and may benefit from deintensification. However, little is known about deintensification practices in this setting. METHODS: We conducted a cohort study from January 1, 2013 to December 31, 2019 among Veterans Affairs (VA) NH residents. Participants were VA NH residents age ≥65 with type 2 diabetes with a NH length of stay (LOS) ≥ 30 days and an HbA1c result during their NH stay. We defined overtreatment as HbA1c <6.5 with any insulin use, and potential overtreatment as HbA1c <7.5 with any insulin use or HbA1c <6.5 on any glucose‐lowering medication (GLM) other than metformin alone. Our primary outcome was continued glycemic overtreatment without deintensification 14 days after HbA1c. RESULTS: Of the 7422 included residents, 17% of residents met criteria for overtreatment and an additional 23% met criteria for potential overtreatment. Among residents overtreated and potentially overtreated at baseline, 27% and 19%, respectively had medication regimens deintensified (73% and 81%, respectively, continued to be overtreated). Long‐acting insulin use and hyperglycemia ≥300 mg/dL before index HbA1c were associated with increased odds of continued overtreatment (odds ratio [OR] 1.37, 95% confidence interval [CI] 1.14–1.65 and OR 1.35, 95% CI 1.10–1.66, respectively). Severe functional impairment (MDS‐ADL score ≥ 19) was associated with decreased odds of continued overtreatment (OR 0.72, 95% CI 0.56–0.95). Hypoglycemia was not associated with decreased odds of overtreatment. CONCLUSIONS: Overtreatment of diabetes in NH residents is common and a minority of residents have their medication regimens appropriately deintensified. Deprescribing initiatives targeting residents at high risk of harms and with low likelihood of benefit such as those with history of hypoglycemia, or high levels of cognitive or functional impairment are most likely to identify NH residents most likely to benefit from deintensification. John Wiley & Sons, Inc. 2022-03-23 2022-07 /pmc/articles/PMC9283249/ /pubmed/35318647 http://dx.doi.org/10.1111/jgs.17735 Text en Published 2022. This article is a U.S. Government work and is in the public domain in the USA. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Regular Issue Content Lederle, Lauren I. Steinman, Michael A. Jing, Bocheng Nguyen, Brian Lee, Sei J. Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes |
title | Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes |
title_full | Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes |
title_fullStr | Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes |
title_full_unstemmed | Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes |
title_short | Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes |
title_sort | glycemic treatment deintensification practices in nursing home residents with type 2 diabetes |
topic | Regular Issue Content |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283249/ https://www.ncbi.nlm.nih.gov/pubmed/35318647 http://dx.doi.org/10.1111/jgs.17735 |
work_keys_str_mv | AT lederlelaureni glycemictreatmentdeintensificationpracticesinnursinghomeresidentswithtype2diabetes AT steinmanmichaela glycemictreatmentdeintensificationpracticesinnursinghomeresidentswithtype2diabetes AT jingbocheng glycemictreatmentdeintensificationpracticesinnursinghomeresidentswithtype2diabetes AT nguyenbrian glycemictreatmentdeintensificationpracticesinnursinghomeresidentswithtype2diabetes AT leeseij glycemictreatmentdeintensificationpracticesinnursinghomeresidentswithtype2diabetes |